Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2014

The triggering events for the sales milestone payments are as follows:


Annual Global Net Sales in a Calendar Year		Milestone Payment⁽¹⁾
$400 million		⁽²⁾
$800 million		⁽³⁾
$1.2 billion		$70 million
$1.6 billion		$175 million

(1)	Each milestone shall only be paid once during the term of the Astellas Collaboration Agreement.

(2)	This milestone totaling $25.0 million was earned and recognized as collaboration revenue during the fourth quarter of 2013 and payment was received in the first quarter of 2014.

(3)	This milestone totaling $50.0 million was earned and recognized as collaboration revenue during the fourth quarter of 2014 and is included in receivable from collaboration partner on the consolidated balance sheet at December 31, 2014. Payment was received during the first quarter of 2015.

Collaboration revenue was as follows:


	Years Ended December 31,
	2014		2013		2012
Collaboration revenue:
Related to U.S. XTANDI sales	$	339,902	$	196,208	$	35,752
Related to ex-U.S. XTANDI sales		49,476		6,338		—
Related to upfront and milestone payments		321,109		70,396		145,944

Total	$	710,487	$	272,942	$	181,696

Collaboration revenue related to U.S. XTANDI sales was as follows:


	Years Ended December 31,
	2014			2013			2012
U.S. XTANDI sales (as reported by Astellas)	$	679,805		$	392,415		$	71,504
Shared U.S. development and commercialization costs		(323,730	)		(241,106	)		(88,908	)

Pre-tax U.S. profit (loss)	$	356,075		$	151,309		$	(17,404	)

Medivation’s share of pre-tax U.S. profit (loss)	$	178,037		$	75,655		$	(8,702	)
Reimbursement of Medivation’s share of shared U.S. costs		161,865			120,553			44,454

Collaboration revenue related to U.S. XTANDI sales	$	339,902		$	196,208		$	35,752

Collaboration revenue related to upfront and milestone payments was as follows:


	Years Ended December 31,
	2014		2013		2012
From Astellas:
Development milestones earned	$	257,000	$	20,000	$	45,000
Sales milestones earned		50,000		25,000		—
Amortization of deferred upfront and development milestones		14,109		25,396		28,914

		321,109		70,396		73,914
From Pfizer:
Amortization of deferred upfront and development milestones		—		—		72,030

Total	$	321,109	$	70,396	$	145,944

The following table summarizes the reductions in R&D expenses related to development cost sharing payments:


	Years Ended December 31,
	2014		2013		2012
Development cost-sharing payments from Astellas	$	63,479	$	46,594	$	47,473
Development cost-sharing payments from Pfizer		—		—		1,740

Total	$	63,479	$	46,594	$	49,213

The following table summarizes the (increases) reductions in SG&A expenses related to commercialization cost-sharing payments:


	Years Ended December 31,
	2014			2013			2012
Commercialization cost-sharing payments to Astellas	$	(36,094	)	$	(11,973	)	$	(3,437	)
Commercialization cost-sharing payments from Pfizer		—			—			9

Total	$	(36,094	)	$	(11,973	)	$	(3,428	)